What is HC Wainwright's Estimate for FULC FY2029 Earnings?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - HC Wainwright issued their FY2029 earnings estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Wednesday, February 26th. HC Wainwright analyst A. Fein expects that the company will earn ($0.95) per share for the year. HC Wainwright has a "Neutral" rating and a $4.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.16) per share.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03).

Separately, Royal Bank of Canada reissued a "sector perform" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Fulcrum Therapeutics has a consensus rating of "Hold" and a consensus price target of $8.63.

Fulcrum Therapeutics Trading Down 9.7 %

Fulcrum Therapeutics stock traded down $0.35 during trading hours on Thursday, reaching $3.24. 702,798 shares of the company were exchanged, compared to its average volume of 469,125. The firm has a market cap of $174.89 million, a price-to-earnings ratio of -10.45 and a beta of 2.03. The stock has a 50-day moving average of $4.11 and a 200 day moving average of $4.51. Fulcrum Therapeutics has a 12 month low of $2.86 and a 12 month high of $13.70.

Remove Ads

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Suvretta Capital Management LLC raised its position in shares of Fulcrum Therapeutics by 182.3% during the fourth quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock worth $15,691,000 after purchasing an additional 2,155,675 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in shares of Fulcrum Therapeutics by 50.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company's stock worth $14,100,000 after buying an additional 1,000,000 shares during the period. State Street Corp lifted its holdings in Fulcrum Therapeutics by 61.4% in the third quarter. State Street Corp now owns 1,680,229 shares of the company's stock worth $5,998,000 after buying an additional 638,955 shares during the period. Woodline Partners LP boosted its holdings in Fulcrum Therapeutics by 110.3% in the fourth quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock worth $6,629,000 after acquiring an additional 739,713 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Fulcrum Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company's stock worth $4,716,000 after buying an additional 13,485 shares in the last quarter. 89.83% of the stock is currently owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.